Superworth

Pulse Biosciences PLSE

Medical - Instruments & Supplies, Healthcare
$52.90
+1.26%
Market cap
$3.8B
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
a sliver of sales
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$1.2M
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−1.6%

Revenue was $1.2M over the last twelve months.

Charts

Financials

Income statement for PLSE, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$0$0$0$0$0$0$0$0$86K$264K$401K$434K
Cost of revenue$0n/an/an/a$0$0$0$0$279K$260K$370K$273K
Gross profit$0n/an/an/a$0$0$0$0−$193K$4K$31K$161K
R&D$7.5M+65%$7.8M$6.7M+16%$7.2M+8%$7.7M+3%$10.7M+37%$10.3M+53%$12.1M+67%$11.4M+48%$10.9M+3%$12.6M+22%$17M+40%
SG&A$3.8M−26%$4.7M$3.9M+4%$4.5M+27%$6M+58%$9.6M+103%$7.7M+100%$8.2M+82%$8.8M+48%$7.3M−24%$6.6M−15%$8.5M+3%
−$11.3M−38%−$12.5M−$10.6M+11%−$11.7M+15%−$13.7M+21%−$20.3M+62%−$18M+70%−$20.3M+73%−$20.4M+49%−$18.3M−10%−$19.1M+6%−$25.3M+25%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Pre-tax income−$10.6M−41%−$11.9M+30%−$10.1M+3%−$11.4M+15%−$12.7M+20%−$19.4M+62%−$16.8M+66%−$19.2M+68%n/an/an/an/a
$0$0$0$0$0$0$0$0n/an/an/an/a
Net income−$10.6M−41%−$11.9M+30%−$10.1M+3%−$11.4M+15%−$12.7M+20%−$19.4M+62%−$16.8M+66%−$19.2M+68%−$19.4M+53%−$17.4M−10%−$18.6M+11%−$24.7M+29%
n/an/an/an/an/an/an/an/an/an/an/an/a
n/an/an/an/an/an/an/an/an/an/an/an/a

Gross profit: 16 periods, Q3 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: Q4 FY20 and Q4 FY21: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY20 and Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Pulse Biosciences' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
PLSEPulse Biosciences$3.8Bn/mn/an/mn/mn/m
NVSTEnvista$4B42.6×28.0×1.4×+12%3.3%
ICUIICU Medical$4.1B138×57.9×1.9×−9%1.4%
BMIBadger Meter$4.5B36.4×47.6×5.1×−2%14.4%
ATRCAtriCure$3B285×61.7×5.3×+14%1.9%
WRBYWarby Parker$2.9B341×359×3.2×+11%0.8%
VNTVontier$5B15.3×13.5×1.6×+1%11.3%
MMSIMerit Medical Systems$5.1B31.7×57.3×3.1×+9%9.9%
HAEHaemonetics$5.5B58.9×51.6×4.0×+0%7.1%
UFPTUFP Technologies$2.2B30.6×25.6×3.5×+7%11.4%
MSAMSA Safety$7.2B23.2×36.2×3.7×+6%16.1%
Peer median$4.3B39.5×49.6×3.4×+7%8.5%

More on Pulse Biosciences

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .